



Personalised Cancer Medicine Flashcards 2025

Pancreatic Cancer



Standard

Microsatellite Instability
(MSI-H, dMMR)*
Germ-line BRCA 1-2
NTRK

* By either IHC (MLH1, PMS2, MSH2 a MSH6) or by genomic study (BAT25 and BAT26, D2S123, D5S346 and D17S250).

Recommended

K-RAS

Currently not recommended

ATM, PALB2, p53, KRAS, CDKN2,
SMAD4, MLL3, TGFB2, ARID1A,
ALK, BRAF, HER2, ROS, RRG1

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System
The **Recommended** category is based on current recommendations by EMEA and FDA

1. Curtin NJ, Drew Y, Sharma-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nat Rev Clin Oncol. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2.
2. a-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nat Rev Clin Oncol. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2.
3. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387.



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

